全文获取类型
收费全文 | 149973篇 |
免费 | 10467篇 |
国内免费 | 763篇 |
专业分类
耳鼻咽喉 | 1401篇 |
儿科学 | 3884篇 |
妇产科学 | 2742篇 |
基础医学 | 20021篇 |
口腔科学 | 3448篇 |
临床医学 | 14535篇 |
内科学 | 32044篇 |
皮肤病学 | 2874篇 |
神经病学 | 14581篇 |
特种医学 | 6094篇 |
外国民族医学 | 6篇 |
外科学 | 22850篇 |
综合类 | 1895篇 |
现状与发展 | 2篇 |
一般理论 | 139篇 |
预防医学 | 10757篇 |
眼科学 | 3167篇 |
药学 | 10432篇 |
中国医学 | 245篇 |
肿瘤学 | 10086篇 |
出版年
2023年 | 744篇 |
2022年 | 490篇 |
2021年 | 2517篇 |
2020年 | 1958篇 |
2019年 | 2817篇 |
2018年 | 3426篇 |
2017年 | 2664篇 |
2016年 | 3045篇 |
2015年 | 3512篇 |
2014年 | 5032篇 |
2013年 | 6805篇 |
2012年 | 10525篇 |
2011年 | 11146篇 |
2010年 | 6349篇 |
2009年 | 6044篇 |
2008年 | 10203篇 |
2007年 | 10884篇 |
2006年 | 10351篇 |
2005年 | 10597篇 |
2004年 | 10003篇 |
2003年 | 9469篇 |
2002年 | 8870篇 |
2001年 | 1459篇 |
2000年 | 1048篇 |
1999年 | 1451篇 |
1998年 | 1753篇 |
1997年 | 1361篇 |
1996年 | 1119篇 |
1995年 | 1250篇 |
1994年 | 1106篇 |
1993年 | 1078篇 |
1992年 | 755篇 |
1991年 | 777篇 |
1990年 | 606篇 |
1989年 | 586篇 |
1988年 | 546篇 |
1987年 | 564篇 |
1986年 | 497篇 |
1985年 | 530篇 |
1984年 | 621篇 |
1983年 | 549篇 |
1982年 | 752篇 |
1981年 | 687篇 |
1980年 | 587篇 |
1979年 | 351篇 |
1978年 | 364篇 |
1977年 | 390篇 |
1976年 | 325篇 |
1975年 | 283篇 |
1974年 | 249篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
Peter Parry Stephen Allison Tarun Bastiampillai 《Child and Adolescent Mental Health》2019,24(1):92-94
‘Paediatric bipolar disorder’ (PBD) remains controversial; because it is based on the hypothesis that bipolar disorder (BD) often begins in childhood with atypical forms of mania. A meta-analysis of 12 epidemiological surveys found a high prevalence of PBD among children and adolescents worldwide (1.8%), however, our study of the measurement issues (Child and Adolescent Mental Health, 23, 2018, 14) found that PBD rates were lower than claimed. Our findings are consistent with the developmental trajectory of BD, as described by most longitudinal studies of high-risk offspring. BD is extremely rare in childhood with nearly all index manic/hypomanic episodes being in midadolescence or later. Treatment for BD should not commence until the first well-defined manic/hypomanic episode, because children and younger adolescents are extremely sensitive to the side effects of second-generation antipsychotics including weight gain, metabolic syndrome, extrapyramidal side effects and the risk of cerebral atrophy, as observed in studies of juvenile animals. 相似文献
52.
Sergey Motov Stefan Mann Jefferson Drapkin Mahlaqa Butt Antonios Likourezos Elizabeth Yetter Jason Brady Nechama Rothberger Ankit Gohel Peter Flom Mo Mai Christian Fromm John Marshall 《The American journal of emergency medicine》2019,37(2):220-227
Study objective
We compare the analgesic efficacy and safety of subdissociative intravenous-dose ketamine (SDK) versus morphine in geriatric Emergency Department (ED) patients.Methods
This was a prospective, randomized, double-blind trial evaluating ED patients aged 65 and older experiencing moderate to severe acute abdominal, flank, musculoskeletal, or malignant pain. Patients were randomized to receive SDK at 0.3?mg/kg or morphine at 0.1?mg/kg by short intravenous infusion over 15?min. Evaluations occurred at 15, 30, 60, 90, and 120?min. Primary outcome was reduction in pain at 30?min. Secondary outcomes included overall rates of adverse effects and incidence of rescue analgesia.Results
Thirty patients per group were enrolled in the study. The primary change in mean pain scores was not significantly different in the ketamine and morphine groups: 9.0 versus 8.4 at baseline (mean difference 0.6; 95% CI ?0.30 to 1.43) and 4.2 versus 4.4 at 30?min (mean difference ?0.2; 95% CI ?1.93 to1.46). Patients in the SDK group reported higher rates of psychoperceptual adverse effects at 15, 30, and 60?min post drug administration. Two patients in the ketamine group and one in the morphine group experienced brief desaturation episodes. There were no statistically significant differences with respect to changes in vital signs and need for rescue medication.Conclusion
SDK administered at 0.3?mg/kg over 15?min provides analgesic efficacy comparable to morphine for short-term treatment of acute pain in the geriatric ED patients but results in higher rates of psychoperceptual adverse effects.ClinicalTrials.gov Registration #: NCT02673372. 相似文献53.
54.
BackgroundDespite the significant role played by vaccines in global health, concerns over vaccine safety have increased tremendously over the years. There have been occasions where vaccines have caused rare, adverse reactions some of which have led to hospitalizations and even death. It is therefore important to establish the safety profile of routinely used vaccines in order to allay fears pertaining to their use.ObjectivesThis review was aimed at pooling together the safety data of selected vaccines used for routine immunization in Africa, a region of the world with paucity of vaccine safety data.MethodsAdverse Events Following Immunization safety data was searched for rotavirus, yellow fever, measles, rubella, tuberculosis (Bacillus Calmette Guerin-BCG), pneumococcal, Haemophilus Influenza type b, polio, meningococcal and the influenza A (H1N1) vaccines in PUBMED, Google Scholar, Clinical trials.gov and Cochrane controlled register of trials databases.ResultsA total of twenty-four serious AEFIs and twenty-three minor AEFIs were identified from the review. The strength of association between AEFIs and vaccine was high for tuberculosis vaccine and moderate for all other vaccines.ConclusionEven though AEFIs (including mild and severe) were identified in the review, all the vaccines studied were generally well tolerated. 相似文献
55.
56.
Hsin-Yi Tseng Jan Dreyer Abdullah Al Emran Dilini Gunatilake Mehdi Pirozyan Carleen Cullinane Ken Dutton-Regester Helen Rizos Nicholas K. Hayward Grant McArthur Peter Hersey Jessamy Tiffen Stuart Gallagher 《International journal of cancer. Journal international du cancer》2020,147(8):2176-2189
The treatment of melanoma has been markedly improved by the introduction of targeted therapies and checkpoint blockade immunotherapy. Unfortunately, resistance to these therapies remains a limitation. Novel anticancer therapeutics targeting the MCL1 anti-apoptotic protein have shown impressive responses in haematological cancers but are yet to be evaluated in melanoma. To assess the sensitivity of melanoma to new MCL1 inhibitors, we measured the response of 51 melanoma cell lines to the novel MCL1 inhibitor, S63845. Additionally, we assessed combination of this drug with inhibitors of the bromodomain and extra-terminal (BET) protein family of epigenetic readers, which we postulated would assist MCL1 inhibition by downregulating anti-apoptotic targets regulated by NF-kB such as BCLXL, BCL2A1 and XIAP, and by upregulating pro-apoptotic proteins including BIM and NOXA. Only 14% of melanoma cell lines showed sensitivity to S63845, however, combination of S63845 and I-BET151 induced highly synergistic apoptotic cell death in all melanoma lines tested and in an in vivo xenograft model. Cell death was dependent on caspases and BAX/BAK. Although the combination of drugs increased the BH3-only protein, BIM, and downregulated anti-apoptotic proteins such as BCL2A1, the importance of these proteins in inducing cell death varied between cell lines. ABT-199 or ABT-263 inhibitors against BCL2 or BCL2 and BCLXL, respectively, induced further cell death when combined with S63845 and I-BET151. The combination of MCL1 and BET inhibition appears to be a promising therapeutic approach for metastatic melanoma, and presents opportunities to add further BCL2 family inhibitors to overcome treatment resistance. 相似文献
57.
58.
Is toombak a risk factor for oral leukoplakia and oral squamous cell carcinoma ? A systematic review
59.
Siavash Rahimi Iolia Akaev Peter A. Brennan Azarel Virgo Carla Marani Ricardo S. Gomez Chit Cheng Yeoh 《Journal of oral pathology & medicine》2020,49(2):110-116
The current three-tier grading system (well, moderate and poorly differentiated) used to morphologically classify head and neck squamous cell carcinoma (HNSCC) is inadequate for categorisation of oropharyngeal squamous cell carcinoma (OPSCC) owing to the lack of prognostic value. The aim of this study was to assess the validity of a classification system for OPSCC based on morphology and human papilloma virus (HPV) infection status. Haematoxylin and eosin slides of 121 patients (100 M, 21 F, age range 40-89 years) with OPSCC were reviewed and categorised as histological types I, II and III. The presence of HPV was assessed by immunohistochemistry with p16 and RNAscope In situ hybridization (ISH). The follow-up period was 36 months. Ninety-six patients were p16+ and clinical stage I. Patient survival with types I, II and III was 93%, 50% and 96%, respectively. Twenty-five patients were p16−: 10 clinical stage I and 15 stage III. Amongst this group, no type I morphology was identified. At follow-up, 65% of type II and 75% of type III patients were alive. All p16+ cases were also positive for E6/E7 mRNA high-risk HPV by ISH, while 23 p16− cases were negative and two were positive. Cox regression identified three predictors of mortality: older age (HR = 1.14, 95% CI = 1.06-1.23, P = .001); female gender (HR = 0.22.95% CI 0.05-0.88, P = .033); and type II morphology (HR = 13.1, 95% CI = 1.09-157.0, P = .043). OPSCC morphological classification in three sub-types, along with HPV infection status, seems to reflect the outcome of patients with OPSCC. 相似文献
60.